Related Experiment Videos
Extracardiac valved conduits in the pulmonary circuit
1Victorian Paediatric Cardiac Surgical Unit, Royal Children's Hospital, Melbourne, Australia.
Insights
Extracardiac valved conduits in congenital heart disease surgery often require replacement. However, replacement procedures can be performed with low risk, even in infants and small children.
Area of Science:
- Cardiovascular Surgery
- Pediatric Cardiology
- Biomaterials Science
Background:
- Extracardiac valved conduits are frequently used in reconstructive surgery for congenital heart disease.
- These conduits have a limited lifespan due to patient growth or device failure, necessitating reoperations.
Purpose of the Study:
- To evaluate the outcomes of extracardiac valved conduit insertions and replacements in a large patient cohort.
- To assess the long-term durability and safety of these conduits, particularly in pediatric patients.
Main Methods:
- Retrospective analysis of 169 extracardiac valved conduit insertions in 141 patients between 1979 and 1989.
- Data collection included patient demographics, conduit types (xenograft and homograft), primary vs. secondary procedures, and reoperation rates.
- Actuarial analysis was used to determine survival and freedom from conduit replacement.
Main Results:
- Overall survival after conduit insertion was 87% at 5 years.
- Freedom from conduit replacement at 5 years was 37%, indicating frequent reoperations.
- Conduit reinsertion after removal had no early or late mortality.
Conclusions:
- Extracardiac valved conduits are associated with a high reoperation rate, especially in younger patients.
- Despite the need for replacement, these procedures can be performed with low mortality, supporting their use in complex congenital heart disease.
- Further research into more durable conduit materials is warranted.
Abstract:
Extracardiac valved conduits represent one of the weakest facets of reconstructive surgery for congenital heart disease in that they invariably need to be replaced because of growth of the patient or because of valve or conduit failure. Between 1979 and 1989, 141 patients had 169 valved conduits placed between the heart and the pulmonary artery circuit. There were 81 male and 60 female patients, aged 2 days to 35 years (mean age, 5.9 years), with 46 patients less than 1 year of age. We performed primary repair in 117 patients; in this group, there have been 28 conduit replacements in 27 patients. In 17 patients initial repair with a conduit was performed elsewhere and we replaced these conduits in 15 and removed them in 2. A further group of 9 patients were seen after repair of tetralogy of Fallot or double-outlet right ventricle, with severe pulmonary incompetence or right ventricular outflow tract aneurysm. All had valved conduits inserted as secondary procedures. The types of valved conduits used were xenograft (n = 126) and homograft (n = 43). There were six hospital deaths (3.6%; 70% confidence limits [CL], 2% to 6%) and seven late deaths (4.1%; CL, 2.5% to 6.5%) in a total of 169 conduit insertions. Forty-five conduits have been removed and 43 reinserted without early or late mortality (0%; CL, 0% to 4%). Actuarial survival after conduit insertion was 87% at 5 years (CL, 80% to 92%), including operative mortality. Actuarial freedom from conduit replacement was 37% at 5 years (CL, 20% to 56%). Conduit insertion in infants and small children ensures subsequent replacement, but this can be done at low risk.(ABSTRACT TRUNCATED AT 250 WORDS)